Key Takeaways
- • APG Asset Management commits $400 million to China Life Science Infrastructure Venture (CLSIV), a $1.5 billion joint venture with Singapore-based CBC Group targeting Asia Pacific life science real estate opportunities.
- • APG secures 80% ownership stake in the venture with a $400 million initial commitment, while CBC contributes $100 million for a 20% stake, establishing a first-mover position in China's life sciences infrastructure market.
- • The venture launches an operating platform, CBC Healthcare Infrastructure Platform (CBC HIP), designed to develop and manage healthcare facilities across nine mainland Chinese cities, beginning with one million square metres of capacity in Shanghai.
- • CBC HIP operates as an integrated infrastructure provider enabling life sciences companies to focus on R&D while outsourcing facility management and development, positioning the venture as a differentiated service model in an underpenetrated market segment.
- • Initial pipeline includes one million square metres secured in Shanghai with identified expansion opportunities in Beijing, signaling aggressive deployment capacity across major Chinese life sciences hubs.
Summary
APG Asset Management, the Dutch pension fund giant managing approximately €610 billion in assets, has committed $400 million as seed capital to establish China Life Science Infrastructure Venture (CLSIV) in partnership with CBC Group, a Singapore-based healthcare investment firm. The broader joint venture targets $1.5 billion in total capital deployment focused on Asia Pacific life science real estate opportunities. The investment represents APG's strategic entry into China's life sciences infrastructure sector, which has experienced rapid growth driven by increased biotech and pharmaceutical R&D activity across the region.
The partnership structure grants APG an 80% ownership stake in CLSIV following the first closing, with CBC contributing $100 million for the remaining 20% equity. The venture establishes two complementary entities: CLSIV serves as the investment vehicle managing capital deployment, while CBC Healthcare Infrastructure Platform (CBC HIP) functions as the operational arm responsible for developing and managing healthcare facilities. According to Hans Kang, CBC HIP's chief executive, the platform positions itself as "the first mover in the market," offering integrated infrastructure solutions that enable life sciences companies to concentrate on core R&D activities while outsourcing facility requirements.
Initial deployment focuses on Shanghai, where CBC HIP has already secured a one million square metre (10.8 million square feet) project pipeline. The venture plans to expand across nine mainland Chinese cities, with Beijing identified as a secondary priority market. This geographic diversification strategy reflects confidence in broader Chinese life sciences growth trajectories and positions the partnership to capture infrastructure demand from both multinational and domestic biotech enterprises establishing or expanding operations in China.
The venture's service model differentiates it within the real estate sector by positioning infrastructure as enabling rather than ancillary. By providing turnkey, integrated facility solutions—encompassing development, management, and specialized life sciences requirements—CBC HIP targets inefficiencies in the current market where life sciences companies typically manage heterogeneous landlord relationships. This operational integration aligns with broader trends in institutional real estate investment toward platform-based, scaled-up management structures that generate recurring revenue and long-term tenant relationships in specialized sectors.
The partnership structure grants APG an 80% ownership stake in CLSIV following the first closing, with CBC contributing $100 million for the remaining 20% equity. The venture establishes two complementary entities: CLSIV serves as the investment vehicle managing capital deployment, while CBC Healthcare Infrastructure Platform (CBC HIP) functions as the operational arm responsible for developing and managing healthcare facilities. According to Hans Kang, CBC HIP's chief executive, the platform positions itself as "the first mover in the market," offering integrated infrastructure solutions that enable life sciences companies to concentrate on core R&D activities while outsourcing facility requirements.
Initial deployment focuses on Shanghai, where CBC HIP has already secured a one million square metre (10.8 million square feet) project pipeline. The venture plans to expand across nine mainland Chinese cities, with Beijing identified as a secondary priority market. This geographic diversification strategy reflects confidence in broader Chinese life sciences growth trajectories and positions the partnership to capture infrastructure demand from both multinational and domestic biotech enterprises establishing or expanding operations in China.
The venture's service model differentiates it within the real estate sector by positioning infrastructure as enabling rather than ancillary. By providing turnkey, integrated facility solutions—encompassing development, management, and specialized life sciences requirements—CBC HIP targets inefficiencies in the current market where life sciences companies typically manage heterogeneous landlord relationships. This operational integration aligns with broader trends in institutional real estate investment toward platform-based, scaled-up management structures that generate recurring revenue and long-term tenant relationships in specialized sectors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.